Talphera (TLPH)
Develops hospital and dialysis therapies, led by Niyad for renal-replacement anticoagulation.
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion Cash and investments of $17.1 million at June 30, 2026 Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced financial results for the second quarter of 2026 and provided a corporate update on the development of nafamostat.
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m.
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m.
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.
Talphera Q4 Earnings Call Highlights
Talphera (NASDAQ: TLPH) used a virtual analyst and investor event to provide a business update and to highlight what company leaders and two clinical experts described as an unmet need in anticoagulation during continuous renal replacement therapy (CRRT). The discussion focused on Talphera's ongoing NEPHRO CRRT registrational study of Niyad (nafamostat) and the practical limitations clinicians
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026 Cash and investments of $20.4 million at December 31, 2025 Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ET SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter and full year 2025 financial results and provided a corporate update.
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT).
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao Teixeira SAN MATEO, Calif., March 2, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced 50% patient enrollment of the NEPHRO-CRRT clinical trial.
Insider Buying: Talphera (NASDAQ:TLPH) Insider Acquires $28,350.00 in Stock
Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Shakil Aslam purchased 35,000 shares of the company's stock in a transaction dated Thursday, February 12th. The stock was bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider directly owned 83,178 shares of
Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock
Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Badri Dasu purchased 35,000 shares of the business's stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider owned 76,230 shares of the company's stock, valued
Insider Buying: Talphera (NASDAQ:TLPH) CFO Buys $36,450.00 in Stock
Talphera, Inc. (NASDAQ: TLPH - Get Free Report) CFO Raffi Asadorian acquired 45,000 shares of the company's stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average cost of $0.81 per share, for a total transaction of $36,450.00. Following the acquisition, the chief financial officer owned 91,256 shares in
Talphera (NASDAQ:TLPH) Shares Down 0.3% – Here’s What Happened
Talphera, Inc. (NASDAQ: TLPH - Get Free Report)'s share price fell 0.3% on Thursday. The company traded as low as $0.7808 and last traded at $0.8079. 39,878 shares traded hands during trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81. Analysts Set New Price
Talphera (NASDAQ:TLPH) Stock Price Down 2.7% – Here’s Why
Talphera, Inc. (NASDAQ: TLPH - Get Free Report)'s stock price fell 2.7% during trading on Monday. The company traded as low as $1.04 and last traded at $1.07. 189,221 shares were traded during trading, a decline of 55% from the average session volume of 416,292 shares. The stock had previously closed at $1.10. Analysts Set
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript
Talphera, Inc. ( TLPH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - CEO & Director Shakil Aslam - Chief Medical Officer Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Welcome to the Talphera Third Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.Talphera.com.
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2025 financial results and provided a corporate update.
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m.